Vitamin D Target Levels for Osteoporosis Patients on Denosumab

Recommended Vitamin D Targets

• The American College of Rheumatology recommends maintaining vitamin D levels of 30-50 ng/mL for patients on glucocorticoid-induced osteoporosis treatment, which includes denosumab 1
• The optimal target range for serum 25(OH)D is 30-50 ng/mL for patients on denosumab, balancing efficacy with safety 1, 2

Safety Concerns and Dosing Strategy

• Hypercalcemia caused by excess vitamin D occurs when 25(OH)D levels exceed 100 ng/mL or daily intake exceeds 100,000 IU 2
• Vitamin D toxicity typically manifests at levels >150 ng/mL, with acute toxicity at >200 ng/mL 3
• Patients on denosumab should receive 600-800 IU daily of vitamin D, with higher doses (1,500-4,000 IU daily) for those at risk of deficiency 1, 2
• Ensure concurrent calcium supplementation of 1,000-1,200 mg daily 1

Monitoring and Maintenance

• Measure serum 25(OH)D levels at least 3 months after starting supplementation to assess response and ensure levels are in the 30-50 ng/mL target range 2
• For patients with documented vitamin D deficiency (<30 ng/mL), initiate 50,000 IU weekly for 8 weeks, then transition to maintenance dosing 2